Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • Ernexa Therapeutics' Operating Expenses fell 2897.36% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 4826.36%. This contributed to the annual value of $16.2 million for FY2024, which is 2292.65% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' Operating Expenses stood at $2.0 million, which was down 2897.36% from $2.5 million recorded in Q2 2025.
  • Ernexa Therapeutics' 5-year Operating Expenses high stood at $86.3 million for Q3 2021, and its period low was $2.0 million during Q3 2025.
  • Its 5-year average for Operating Expenses is $10.2 million, with a median of $5.3 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 288017.27% in 2021, then crashed by 9037.51% in 2022.
  • Over the past 5 years, Ernexa Therapeutics' Operating Expenses (Quarter) stood at $86.3 million in 2021, then plummeted by 94.51% to $4.7 million in 2022, then rose by 20.67% to $5.7 million in 2023, then plummeted by 52.8% to $2.7 million in 2024, then decreased by 26.13% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.5 million for Q2 2025, and $2.7 million during Q1 2025.